2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus 2024, 10: 812-817. PMID: 38580524, DOI: 10.1016/j.euf.2024.03.006.Peer-Reviewed Original ResearchTime to treatment failureDisease control rateRenal cell carcinomaSynchronous metastasesMetachronous metastasesOverall survivalMetachronous metastatic renal cell carcinomaMedian time to treatment failureICI-based combination therapyAssociated with worse OSMetastatic renal cell carcinomaFirst-line immunotherapyICI-based combinationsRenal cell carcinoma diagnosisDiagnosis of kidney cancerHypothesis-generating studyMedian OSMetachronous groupPoor OSTreatment failureCombination therapyMetastasis onsetCell carcinomaSurvival outcomesClinical outcomes
2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Navani V, Wells J, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Meza L, Pal S, Donskov F, Beuselinck B, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer 2022, 21: 106.e1-106.e8. PMID: 35945133, DOI: 10.1016/j.clgc.2022.07.008.Peer-Reviewed Original ResearchConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabOverall survivalTreatment failureAdvanced renal cell carcinomaActivity of cabozantinibClinically meaningful activityMedian TTFEffects of cabozantinibGrowth factor inhibitorsRenal cell carcinomaMultivariate Cox regressionMedian OSRetrospective observational naturePoor riskCell carcinomaFactor inhibitorsCabozantinibCox regressionResponse ratePatientsOverall populationObservational natureVEGFiMonthsFirst-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Roussel E, Kinget L, Beuselinck B, Albersen M, Wells C, Ernst M, Donskov F, Schmidt A, Szabados B, Pal S, Meza L, Agarwal N, Weickhardt A, Davis I, Alva A, Wood L, Porta C, Choueiri T, Heng D, Navani V. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 317-317. DOI: 10.1200/jco.2022.40.6_suppl.317.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaPancreatic metastasisOverall survivalVascular endothelial growth factorRenal cell carcinomaMedian OSCell carcinomaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupMetastatic renal cell carcinoma patientsMedian OS of patientsRetrospective analysis of patientsEfficacy of first-lineKaplan Meier survival curvesOS of patientsSite of metastasisFirst-line therapyAssociated with improved outcomesIndolent biological behaviorAnalysis of patientsAnti-angiogenic therapyVEGF monotherapyEndothelial growth factorLow event ratesImproved OS
2021
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil count
2019
Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma
Bergerot P, Bergerot C, Philip E, Meza L, Dizman N, Hsu J, Pal S. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma. Kidney Cancer 2019, 3: 63-70. DOI: 10.3233/kca-180047.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorHigher body mass indexBody mass indexLower body mass indexMedian overall survivalOverall survivalMass indexMetastatic renal cell carcinoma patientsMetastatic renal cell carcinomaEffect of BMIRenal cell carcinoma patientsImproved overall survivalCell carcinoma patientsBetter overall survivalKaplan-Meier methodContext of immunotherapyRenal cell carcinomaPatients 66Median OSCarcinoma patientsClinical outcomesHigher BMIRetrospective studyCell carcinomaClinical variables